PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
NVAX vs. MRNA
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between NVAX and MRNA is 0.44, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


-0.50.00.51.00.4

Performance

NVAX vs. MRNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Novavax, Inc. (NVAX) and Moderna, Inc. (MRNA). The values are adjusted to include any dividend payments, if applicable.

-100.00%0.00%100.00%200.00%300.00%400.00%500.00%600.00%AugustSeptemberOctoberNovemberDecember2025
-79.51%
83.12%
NVAX
MRNA

Key characteristics

Sharpe Ratio

NVAX:

0.70

MRNA:

-1.05

Sortino Ratio

NVAX:

2.43

MRNA:

-1.82

Omega Ratio

NVAX:

1.30

MRNA:

0.77

Calmar Ratio

NVAX:

1.01

MRNA:

-0.71

Martin Ratio

NVAX:

2.60

MRNA:

-1.42

Ulcer Index

NVAX:

38.31%

MRNA:

46.36%

Daily Std Dev

NVAX:

143.47%

MRNA:

62.64%

Max Drawdown

NVAX:

-98.82%

MRNA:

-93.03%

Current Drawdown

NVAX:

-97.37%

MRNA:

-92.97%

Fundamentals

Market Cap

NVAX:

$1.37B

MRNA:

$13.11B

EPS

NVAX:

-$2.15

MRNA:

-$5.86

PEG Ratio

NVAX:

0.00

MRNA:

0.00

Total Revenue (TTM)

NVAX:

$593.85M

MRNA:

$2.26B

Gross Profit (TTM)

NVAX:

$448.38M

MRNA:

$1.46B

EBITDA (TTM)

NVAX:

-$54.57M

MRNA:

-$2.28B

Returns By Period

In the year-to-date period, NVAX achieves a 4.48% return, which is significantly higher than MRNA's -18.09% return.


NVAX

YTD

4.48%

1M

-2.67%

6M

-39.35%

1Y

104.38%

5Y*

7.93%

10Y*

-24.87%

MRNA

YTD

-18.09%

1M

-11.21%

6M

-71.88%

1Y

-65.62%

5Y*

10.58%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

NVAX vs. MRNA — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NVAX
The Risk-Adjusted Performance Rank of NVAX is 7878
Overall Rank
The Sharpe Ratio Rank of NVAX is 7070
Sharpe Ratio Rank
The Sortino Ratio Rank of NVAX is 8686
Sortino Ratio Rank
The Omega Ratio Rank of NVAX is 8484
Omega Ratio Rank
The Calmar Ratio Rank of NVAX is 7979
Calmar Ratio Rank
The Martin Ratio Rank of NVAX is 7070
Martin Ratio Rank

MRNA
The Risk-Adjusted Performance Rank of MRNA is 55
Overall Rank
The Sharpe Ratio Rank of MRNA is 33
Sharpe Ratio Rank
The Sortino Ratio Rank of MRNA is 33
Sortino Ratio Rank
The Omega Ratio Rank of MRNA is 44
Omega Ratio Rank
The Calmar Ratio Rank of MRNA is 88
Calmar Ratio Rank
The Martin Ratio Rank of MRNA is 77
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

NVAX vs. MRNA - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Novavax, Inc. (NVAX) and Moderna, Inc. (MRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for NVAX, currently valued at 0.70, compared to the broader market-2.000.002.004.000.70-1.05
The chart of Sortino ratio for NVAX, currently valued at 2.43, compared to the broader market-4.00-2.000.002.004.002.43-1.82
The chart of Omega ratio for NVAX, currently valued at 1.30, compared to the broader market0.501.001.502.001.300.77
The chart of Calmar ratio for NVAX, currently valued at 1.01, compared to the broader market0.002.004.006.001.01-0.71
The chart of Martin ratio for NVAX, currently valued at 2.60, compared to the broader market-10.000.0010.0020.0030.002.60-1.42
NVAX
MRNA

The current NVAX Sharpe Ratio is 0.70, which is higher than the MRNA Sharpe Ratio of -1.05. The chart below compares the historical Sharpe Ratios of NVAX and MRNA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.501.00AugustSeptemberOctoberNovemberDecember2025
0.70
-1.05
NVAX
MRNA

Dividends

NVAX vs. MRNA - Dividend Comparison

Neither NVAX nor MRNA has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

NVAX vs. MRNA - Drawdown Comparison

The maximum NVAX drawdown since its inception was -98.82%, which is greater than MRNA's maximum drawdown of -93.03%. Use the drawdown chart below to compare losses from any high point for NVAX and MRNA. For additional features, visit the drawdowns tool.


-95.00%-90.00%-85.00%-80.00%-75.00%AugustSeptemberOctoberNovemberDecember2025
-97.37%
-92.97%
NVAX
MRNA

Volatility

NVAX vs. MRNA - Volatility Comparison

The current volatility for Novavax, Inc. (NVAX) is 23.37%, while Moderna, Inc. (MRNA) has a volatility of 26.00%. This indicates that NVAX experiences smaller price fluctuations and is considered to be less risky than MRNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%AugustSeptemberOctoberNovemberDecember2025
23.37%
26.00%
NVAX
MRNA

Financials

NVAX vs. MRNA - Financials Comparison

This section allows you to compare key financial metrics between Novavax, Inc. and Moderna, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab